Disclosure from Vaping Professionals Wanted: Exciting Rewards Await!

Industry Insight by 2FIRSTS
Jan.16.2024
Disclosure from Vaping Professionals Wanted: Exciting Rewards Await!
Rewards ranging from CN¥200 to CN¥1000 for adopted releases of information. Looking forward to your participation!

To obtain first-hand industry information, 2FIRSTS is thrilled to announce the launch of a rewarding tip-off initiative starting from January 16th. We have established a dedicated mailbox to encourage professionals within the industry to share exclusive leads in exchange for attractive rewards.

 

The information you provide can include, but is not limited to, industry dynamics, market insights, unforeseen events, company developments, and more. As long as your tip meets our requirements, 2FIRSTS will promptly assign editors to follow up, ensuring that the information receives timely attention.

 

Upon verification and adoption of the tip, the informant stands a chance to receive cash rewards ranging from ¥200 to ¥1000 (amounts may vary). In case of duplicate tips, only the first informant will be eligible for the reward.

 

Terms and Conditions:

 

Time Frame: 

Effective from January 16, 2023, ongoing.

 

Reward Mechanism: 

Cash rewards ranging from ¥200 to ¥1000 for adopted tips (only the first informant will be rewarded in case of duplicate tips).

 

Tip-off Content: 

Inclusive of, but not limited to, industry dynamics, market information, unforeseen events, company movements within the electronic cigarette industry.

 

Participation Method: 

If you are a professional in the e-cigarette industry, simply send the crucial information you possess to our dedicated email address [info@2firsts.com]. We will promptly follow up on your tip.

 

Through this interactive platform, we look forward to establishing closer connections with industry professionals and collectively driving the development of the vaping industry. We appreciate everyone's continuous support for 2FIRSTS and eagerly await your active participation in creating more enriching and accurate industry content!

 

2FIRSTS Editorial Department

 


About 2FIRSTS

 

Established in early 2022, 2FIRSTS is a globally influential aerosol technology media and think tank. Our core readership includes regulatory authorities from various countries, international new tobacco companies, distributors, supply chain enterprises, non-profit organizations, and media outlets. 2FIRSTS brings readers the latest global information, forward-thinking topics, in-depth analyses, insights, and rich data and information. We are committed to promoting high-quality development of the global new tobacco industry through media and research, contributing to harm reduction initiatives worldwide.

 

2FIRSTS has currently established platforms such as 2firsts.cn (Chinese), 2firsts.com (International), and 2firsts.com/es (Spanish), with a daily visitation exceeding 10,000.

 

With offices in Shenzhen, Hong Kong, New York, Europe, and collaborations with international new tobacco companies, regulatory authorities, and media outlets, 2FIRSTS maintains excellent cooperation and close communication. We are also proud partners and official media representatives for major global new tobacco exhibitions.

JTI Makes Third Bet on South Korea as Ploom AURA Enters a Market Dominated by lil and IQOS
JTI Makes Third Bet on South Korea as Ploom AURA Enters a Market Dominated by lil and IQOS
Japan Tobacco International is stepping up its heated tobacco push in South Korea with Ploom AURA. Since its official launch in April 2026, the device's limited First Edition and Glacier White version have sold out, while distribution has expanded across Seoul, Incheon, Gyeonggi Province and airport duty-free channels. The rollout marks JTI's third major attempt to build a stronger heated tobacco position in South Korea, following Ploom TECH in 2019 and Ploom X Advanced in 2024. At the group level, JT plans to invest about ¥800 billion, approximately $5 billion, in reduced-risk products from 2026 through 2028, with heated products and Ploom identified as its primary investment priority.
Aug.14
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
French vaping company Kumulus Vape reported first-half 2026 revenue of €25.5 million, down 8.3% year over year, as its core B2B distribution business fell 11% to €21.6 million. B2C and store-network revenue rose 5.6% and 17.8%, respectively. Commercial margin increased to 26.3% from 21.7%, while net profit rose 24.1% to €0.8 million. The company attributed the profitability improvement to catalog optimization, logistics restructuring and the ramp-up of Labster, its in-house production unit for proprietary brands.
Market
Sep.17 by 2Firsts Perspectives
U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
The U.S. Court of Appeals for the Ninth Circuit upheld the FDA’s denial of MH Global LLC’s applications to market flavored electronic nicotine delivery systems (ENDS). The court ruled that FDA’s comparative-efficacy framework, which requires applicants to show that flavored products provide greater cessation or switching benefits than tobacco-flavored alternatives, is consistent with the Tobacco Control Act’s “appropriate for the protection of the public health” standard. The court also found that FDA was not required to establish the framework through notice-and-comment rulemaking.
Aug.26
BAT Expands ITC Infotech Partnership Across Poland, Romania and India to Advance AI
BAT Expands ITC Infotech Partnership Across Poland, Romania and India to Advance AI
ITC Infotech has expanded its multi-year strategic technology partnership with British American Tobacco (BAT), providing technology services across Poland, Romania and India while continuing to support BAT's newly launched Future Capabilities Centre in India and existing technology hubs in Malaysia and Mexico. The companies said the agreement will focus on AI-enabled innovation, technology capability building and greater operational efficiency. The partnership also aligns with BAT's broader Fit2Win transformation programme, under which the group is expanding the use of external technology and business-services partners to simplify its global operating model.
Aug.13
China Tobacco Plans CNY 60 Billion Investment in ICBC, Agricultural Bank as Strategic Ties Extend Beyond Equity
China Tobacco Plans CNY 60 Billion Investment in ICBC, Agricultural Bank as Strategic Ties Extend Beyond Equity
China National Tobacco Corporation and several subsidiaries plan to invest a combined CNY 60 billion ($8.7 billion) in share placements by Industrial and Commercial Bank of China and Agricultural Bank of China as strategic investors. The agreements extend beyond equity investment to corporate governance, banking services and supply-chain finance. The filings also disclose 2025 data on China Tobacco’s tax and profit contributions and industry scale.
Sep.07
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22